Silence Therapeutics Financials - Benzinga

Silence Therapeutics PLC

SLNNASDAQ

Trade with Public

Trade with Public

$13.53

0.110.82%

At close: Aug 31, 5:00 PM EST

$13.53

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Silence Therapeutics Financials

Silence Therapeutics (SLN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 84.21 percent increase over losses of $(0.57) per share from

Benzinga Newsdesk

PRO
Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from

Benzinga Newsdesk

Silence Therapeutics Q4 Earnings Assessment

Benzinga Insights

PRO
Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from

Benzinga Newsdesk

PRO
CORRECTION: Silence Therapeutics Q3 EPADS $(0.45) Misses $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 80 percent decrease over losses of $(0.25) per share

Benzinga Newsdesk

PRO
CORRECTION: Silence Therapeutics Q2 EPS $(0.57) Misses $(0.23) Estimate, Sales $224.000K Miss $5.430M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.23) by 147.83 percent. This is a 35.71 percent decrease over losses of $(0.42) per share

Benzinga Newsdesk